first amended and restated Evaluation AGREEMENT BY AND BETWEEN FIBROGEN, INC. AND FORTIS Therapeutics, INC. JUNE 6, 2024Evaluation Agreement • August 6th, 2024 • Fibrogen Inc • Pharmaceutical preparations • Delaware
This First Amended and Restated Evaluation Agreement (this “Agreement”) is entered into as of June 6, 2024 (the “Restatement Effective Date”) by and between FIBROGEN, INC., a Delaware corporation, with its principal place of business at 409 Illinois Street, San Francisco, California 94158 (“FibroGen”), and FORTIS THERAPEUTICS, INC., having an address at 11099 North Torrey Pines Road, Suite 290, La Jolla, CA 92037 (“Fortis”). FibroGen and Fortis may be referred to herein individually as a “Party”, or collectively as the “Parties”.
Option Agreement and Plan of Merger BY AND among Fibrogen, Inc., Fortis therapeutics, Inc. and SHAREHOLDER REPRESENTATIVE SERVICES LLC, as Sellers’ Representative Dated as of JUNE 6, 2024Option Agreement and Plan of Merger • August 6th, 2024 • Fibrogen Inc • Pharmaceutical preparations
This First Amended and Restated Option Agreement and Plan of Merger (this “Option Agreement”) dated as of June 6, 2024 (the “Restatement Effective Date”) amends and restates that certain Option Agreement and Plan of Merger, effective as of May 5, 2023 (the “Original Effective Date” and such agreement, the “Original Agreement”), by and among FibroGen, Inc., a Delaware corporation (“FibroGen”), Fortis Therapeutics, Inc., a Delaware corporation (“Fortis”), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the Sellers’ Representative.
